Evidence map›Paper›PMID 26535882›Full record

SynthesisMedical science monitor : international medical journal of experimental and clinical research2015

A Positive Role of Cytokine-Induced Killer Cell Therapy on Gastric Cancer Therapy in a Chinese Population: A Systematic Meta-Analysis.

Kang Liu, Guiqin Song, Xin Hu, Yuchuan Zhou, Ying Li, Qiaoling Chen, Gang Feng

Open access · hybridAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Medical science monitor : international medical journal of experimental and clinical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Immunotherapy for Gastric Cancer: Time for a Personalized Approach?International journal of molecular sciences · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kang LiuInstitute of Tissue Engineering and Stem Cells, North Sichuan Medical College, Nanchong, Sichuan, China (mainland).
Guiqin SongInstitute of Tissue Engineering and Stem Cells, North Sichuan Medical College, Nanchong, Sichuan, China (mainland).
Xin HuBiotherapy Center, Nanchong Central Hospital, Nanchong, Sichuan, China (mainland).
Yuchuan ZhouBiotherapy Center, Nanchong Central Hospital, Nanchong, Sichuan, China (mainland).
Ying LiBiotherapy Center, Nanchong Central Hospital, Nanchong, Sichuan, China (mainland).
Qiaoling ChenBiotherapy Center, Nanchong Central Hospital, Nanchong, Sichuan, China (mainland).
Gang FengInstitute of Tissue Engineering and Stem Cells, North Sichuan Medical College, Nanchong, Sichuan, China (mainland).
Nanchong Central Hospital · CNNorth Sichuan Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChemotherapy and radiation therapy provide limited improvement in survival of gastric cancer patients after tumor resection. It is essential to develop a novel therapeutics for gastric cancer. In the recent years, cytokine-induced killer cells (CIKs)-based adoptive immune therapy has been explored in gastric cancer patients. Due to the small number of patients included in each clinical trial and low-power statistical analysis, the effectiveness of this approach is still unclear. To address this issue, we systemically analyzed the relevant clinical trial data published in recent years by powerful statistical meta-analysis. MATERIAL AND

methodsClinical data was searched by multiple electronic databases with a term "gastric cancer" and "cytokine-induced killer cells". Six relevant clinical trials with case-control studies were extracted for our meta-analysis, including 318 patients receiving CIK cell therapy and 369 patients receiving conventional therapy.

resultsOverall survival (OS) and odds ratio (OR) were analyzed for patients at 1, 2, 3, and 5 years post-CIK cell therapy and post-conventional therapy. Heterogeneity and publication bias were analyzed for included data quality and publication bias. Our meta-analysis from 6 clinical trials suggests that CIK cell therapy significantly increased 5-year OS from 27±2.44% to 49±7.62% (p<0.05) and 5-year OR up to 1.77 (p<0.05). The increased 5-year survival rate was also highly correlated with the increased CD3+ T cell number and ratio of CD4+/CD8+ in the CIK treated patients.

conclusionsCIK cell therapy significantly increased 5-year survival rate compared to conventional chemotherapy among gastric cancer patients. The study provides powerful statistical evidence for large-scale clinical trials with CIK cell therapy.

Indexed as

Cell- and Tissue-Based TherapyAdaptive ImmunityAgedCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesChinaClinical Trials as TopicCytokine-Induced Killer CellsFemaleHumansImmunotherapyMaleMiddle AgedOdds RatioStomach NeoplasmsSurvival Rate

Identifiers

PMID26535882
PMCPMC4638280
OpenAlexW2097619011

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.